Edition:
India

People: Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

94.45USD
24 May 2019
Change (% chg)

$2.31 (+2.51%)
Prev Close
$92.14
Open
$92.66
Day's High
$96.34
Day's Low
$91.86
Volume
60,538
Avg. Vol
80,511
52-wk High
$127.74
52-wk Low
$64.25

Mellett, Paul 

Mr. Paul J. Mellett Jr. is Chief Financial Officer, Senior Vice President - Finance & Administration of the Company. From April 2001 through August 2003, he held the position of Senior Vice President and Chief Financial Officer of Essential Therapeutics, Inc., a publicly-held biotechnology company. Previously, Mr. Mellett was the Chief Financial Officer and Vice President of Administration at GelTex Pharmaceuticals, Inc., a publicly held biotechnology company that was acquired by Genzyme Corporation in December 2000. From 1994 to 1997, Mr. Mellett served as Chief Financial Officer of Marshall Contractors, a construction management firm specializing in the pharmaceutical, biotechnology and semiconductor industries, which was acquired by Fluor Corporation in 1996. From 1977 to 1994, Mr. Mellett was employed with Deloitte & Touche LLP, a public accounting firm, and was promoted to Audit Partner in 1989. Mr. Mellett received a B.S. in Business Administration from Boston College in 1977.

Basic Compensation

Total Annual Compensation, USD 394,937
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,026,340
Fiscal Year Total, USD 1,421,280

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Bruce Carter

394,190

Jay Luly

4,508,740

Paul Mellett

1,421,280

Yat Sun Or

1,524,000

Nathaniel Gardiner

1,376,110

Nathalie Adda

1,514,080
As Of  30 Sep 2018